ERVEBO® - EBOLA ZAIRE VACCINE: A TALE OF INNOVATION AND COLLABORATION

Beth-Ann Coller, Ph.D.
Executive Director, Global Clinical Development
Merck Research Laboratories
North Wales, Pennsylvania 19454

Ebola continues to cause significant morbidity and mortality in regions of the world where the provision of healthcare and vaccine are difficult. The Merck vaccine is a live recombinant vesicular stomatitis virus (VSV) containing the Zaire Ebola virus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP). Its safety, efficacy, or immunogenicity has been evaluated in 13 clinical trials, and the vaccine has been approved for use in humans by the European Medicines Agency, United States Food and Drug Administration, several African countries, and has been prequalified by the World Health Organization. More than 300,000 people have received the vaccine to date. Safety, immunogenicity, and efficacy data from across the program will be discussed as well as the use of the vaccine in the context of outbreak response.

Wednesday, April 1, 2020 via Zoom @ 12:00 noon

Zoom Link: https://hawaii.zoom.us/j/4234371004
Zoom ID: 423 437 1004

For further information, contact Dr. Vivek Nerurkar (ph. 692-1668; email: nerurkar@hawaii.edu)
Seminar Schedule @ http://manoa.hawaii.edu/tropicalmedicine/?page_id=4667

This seminar is supported in part by grant P30GM114737 (COBRE) from the National Institutes of Health.